Bioinvent
Bioinvent: No drama in Q1 - key milestones approaching (Redeye)
2019-05-22 17:18
Today’s Q1 2019 earnings report was mostly uneventful. All the 2019 catalyst remain on track, and the closest is a first look of the data from the ongoing combination study with BI-1206, expected in mid-June. Following the report, we reiterate our base case fair value of SEK 4.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se